Jerrold B. Grossman, a director at ADMA Biologics, Inc. (NASDAQ:ADMA), engaged in an open market purchase of the company's common stock on May 12, 2026. The transaction involved acquiring 12,500 shares at a price point of $8.01 per share, resulting in a total expenditure of $100,125.
This recent buying activity comes into focus given the current trading context for ADMA Biologics common stock. The stock is currently positioned near its 52-week low of $7.21 and has experienced a decline of 53% year-to-date. Analysis from InvestingPro suggests that, at present levels, ADMA may be undervalued, noting that the shares are trading considerably below the calculated Fair Value, placing the company among stocks flagged as highly undervalued.
Director Holdings and Ownership Structure
Following this acquisition, Grossman's direct ownership of common stock increased to 513,884 shares. This total holding comprises two distinct components: 503,194 shares that are outright owned by the reporting person, and 10,690 Restricted Stock Units (RSUs). These RSUs have vesting schedules split across two dates: half of them are slated to vest on August 9, 2026, while the remaining portion is scheduled to vest on February 9, 2027. The vesting of these units remains contingent upon Grossman's continued service as a director.
Beyond his direct ownership, Grossman maintains significant indirect holdings in ADMA Biologics common stock through several corporate entities:
-
Risks
- Market Volatility near 52-Week Low
- Earnings Per Share (EPS) Shortfall
- Revenue Underperformance
More from Insider Trading